Business Description
DiaMedica Therapeutics is a Minneapolis-based drug development company working to create new treatments for patients with serious conditions affecting blood flow, including stroke, kidney disease, and pregnancy complications. Its primary drug, DM199, is currently being tested in late-stage clinical trials, while a second compound targeting inflammatory conditions remains in earlier stages of research. Founded in 2000, the company is focused on turning its pipeline of experimental therapies into approved medicines that address significant unmet medical needs.
